Technical Analysis for MDNA - Medicenna Therapeutics Corp.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 2.220 | 4.23% | 0.090 |
Earnings due: Aug 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 50 DMA Resistance | Bearish | 4.23% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 4.23% | |
| Crossed Above 20 DMA | Bullish | 4.23% | |
| Pocket Pivot | Bullish Swing Setup | 4.23% | |
| Wide Range Bar | Range Expansion | 4.23% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 14 hours ago |
| Possible Inside Day | about 14 hours ago |
| Upper Bollinger Band Resistance | about 18 hours ago |
| 50 DMA Resistance | about 18 hours ago |
| Rose Above 50 DMA | about 18 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 2024-08-02
Medicenna Therapeutics Corp. Description
Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinic Drug Cancer Medical Specialties Oncology Clinical Trial Cancers Clinical Medicine Tumor Immunotherapy Stem Cells Treatment Of Cancer Cancer Immunotherapy Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.98 |
| 52 Week Low | 0.215 |
| Average Volume | 108,902 |
| 200-Day Moving Average | 1.267 |
| 50-Day Moving Average | 2.138 |
| 20-Day Moving Average | 1.973 |
| 10-Day Moving Average | 2.021 |
| Average True Range | 0.157 |
| RSI (14) | 58.68 |
| ADX | 13.55 |
| +DI | 28.960 |
| -DI | 15.909 |
| Chandelier Exit (Long, 3 ATRs) | 1.819 |
| Chandelier Exit (Short, 3 ATRs) | 2.241 |
| Upper Bollinger Bands | 2.186 |
| Lower Bollinger Band | 1.759 |
| Percent B (%b) | 1.08 |
| BandWidth | 21.617 |
| MACD Line | -0.003 |
| MACD Signal Line | -0.036 |
| MACD Histogram | 0.033 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.385 | ||||
| Resistance 3 (R3) | 2.373 | 2.307 | 2.358 | ||
| Resistance 2 (R2) | 2.307 | 2.265 | 2.313 | 2.348 | |
| Resistance 1 (R1) | 2.263 | 2.239 | 2.285 | 2.275 | 2.339 |
| Pivot Point | 2.197 | 2.197 | 2.208 | 2.203 | 2.197 |
| Support 1 (S1) | 2.153 | 2.155 | 2.175 | 2.165 | 2.101 |
| Support 2 (S2) | 2.087 | 2.129 | 2.093 | 2.092 | |
| Support 3 (S3) | 2.043 | 2.087 | 2.083 | ||
| Support 4 (S4) | 2.055 |
